Welcome to our dedicated page for BOUNDLESS BIO SEC filings (Ticker: BOLD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page compiles SEC filings for Boundless Bio, Inc. (Nasdaq: BOLD), a clinical-stage oncology company focused on extrachromosomal DNA (ecDNA) biology and ecDNA-directed therapeutics (ecDTx) for oncogene-amplified cancers. The filings provide official details on the company’s financial condition, governance, and key corporate events.
Among the documents available are Current Reports on Form 8-K. For example, Boundless Bio filed 8-Ks dated August 5, 2025, and November 5, 2025, each noting that the company issued press releases announcing financial results for the quarters ended June 30, 2025, and September 30, 2025, respectively. These 8-Ks explain that the earnings press releases are furnished as exhibits and describe how they are treated under Section 18 of the Securities Exchange Act of 1934.
An additional Form 8-K dated June 23, 2025, reports the results of the company’s annual meeting of stockholders. This filing summarizes stockholder votes on the election of Class I directors to serve until the 2028 annual meeting of stockholders and on the ratification of KPMG LLP as Boundless Bio’s independent registered public accounting firm for the fiscal year ending December 31, 2025. Vote totals for each proposal are presented in tabular form within the filing.
In its press releases, Boundless Bio also directs readers to annual and quarterly reports, such as its Form 10-K for the year ended December 31, 2024, and its Form 10-Q for the quarter ended September 30, 2025, for detailed risk factor discussions and additional financial and operational information. Those filings, together with 8-Ks, form the core of the company’s SEC disclosure record.
On Stock Titan, these filings are paired with AI-powered summaries that highlight key points from lengthy documents, helping readers quickly understand items such as earnings announcements, stockholder vote outcomes, and updates referenced in 8-Ks. Real-time integration with the SEC’s EDGAR system means new BOLD filings appear promptly, while structured views make it easier to locate specific forms, including 8-Ks related to financial results and governance matters. This allows users to review Boundless Bio’s regulatory history and disclosures that frame the development of its ecDTx pipeline and clinical programs.
Boundless Bio, Inc. (Nasdaq: BOLD) filed a Form 8-K detailing the results of its 23 June 2025 annual meeting of stockholders.
- Director elections: Class I nominees Christine Brennan, Ph.D. (9,252,440 for / 5,046,258 withheld) and Nancy Whiting, Pharm.D. (9,758,214 for / 4,540,484 withheld) were elected to serve until the 2028 annual meeting; 3,540,518 broker non-votes were recorded for each candidate.
- Auditor ratification: Shareholders ratified KPMG LLP as independent registered public accounting firm for fiscal 2025 with 17,791,309 votes for, 47,807 against and 100 abstentions.
No other matters were brought before shareholders and no additional material disclosures were made.